IQVIA Holdings Inc. $IQV Stock: Community Trust & Investment Co. Trims Stake

Key Points

• Community Trust & Investment Co. reduced its IQVIA stake by 13.8% in the third quarter, selling 12,783 shares and retaining 79,885 shares valued at approximately $21.5 million. Institutional investors collectively own 89.62% of the company.
• Analysts remain broadly positive, with IQVIA receiving a consensus “Moderate Buy” rating and an average price target of $276. Several brokerages recently raised their targets, including Truist Financial to $329 and Mizuho to $300.
• IQVIA reported quarterly EPS of $3.15, beating estimates of $3.03, while revenue reached $4.37 billion and increased 8.7% year over year. The stock opened at $270.80, near its 12-month high of $277.40.

Community Trust & Investment Co. trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,885 shares of the medical research company's stock after selling 12,783 shares during the quarter. IQVIA accounts for 1.0% of Community Trust & Investment Co.'s portfolio, making the stock its 27th largest position. Community Trust & Investment Co.'s holdings in IQVIA were worth $21,477,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Birchbrook Inc. raised its holdings in shares of IQVIA by 1.8% in the 3rd quarter. Birchbrook Inc. now owns 3,857 shares of the medical research company's stock worth $1,037,000 after buying an additional 70 shares in the last quarter. Mather Group LLC. raised its holdings in shares of IQVIA by 10.2% in the third quarter. Mather Group LLC. now owns 975 shares of the medical research company's stock valued at $262,000 after buying an additional 90 shares during the last quarter. Fortitude Family Office LLC grew its holdings in IQVIA by 17.2% during the 3rd quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company's stock worth $119,000 after acquiring an additional 65 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new stake in IQVIA in the 3rd quarter valued at about $1,387,000. Finally, B. Riley Wealth Advisors Inc. lifted its holdings in IQVIA by 38.7% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 2,126 shares of the medical research company's stock worth $572,000 after buying an additional 593 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IQV. JPMorgan Chase & Co. boosted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Truist Financial restated a "buy" rating and set a $329.00 target price (up from $300.00) on shares of IQVIA in a research note on Monday, September 28th. Weiss Ratings upgraded shares of IQVIA from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, September 24th. Morgan Stanley raised their target price on IQVIA from $240.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, September 17th. Finally, Mizuho increased their price target on IQVIA from $275.00 to $300.00 and gave the company an "outperform" rating in a research note on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $276.00.

IQVIA Stock Performance

NYSE IQV opened at $270.80 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a fifty day simple moving average of $260.18 and a 200 day simple moving average of $212.46. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $277.40. The company has a market cap of $44.57 billion, a P/E ratio of 33.60, a PEG ratio of 2.27 and a beta of 1.17.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.